Fulgent Genetics (FLGT) Common Equity (2015 - 2026)

Fulgent Genetics (FLGT) has 12 years of Common Equity data on file, last reported at $1.0 billion in Q1 2026.

• Quarterly Common Equity fell 6.5% year-over-year to $1.0 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (down 6.5% YoY) and the FY2025 annual result came in at $1.1 billion, down 1.52% from the prior year.
• Common Equity declined to $1.0 billion in Q1 2026 per FLGT's latest filing, from $1.1 billion in the prior quarter.
• The five-year high for Common Equity was $1.3 billion in Q1 2022, with the low at $1.0 billion in Q1 2026.
• Average Common Equity over 5 years is $1.2 billion, with a median of $1.1 billion recorded in 2023.
• Year-over-year, Common Equity jumped 63.8% in 2022 and decreased 11.21% in 2024.
• Fulgent Genetics' Common Equity stood at $1.3 billion in 2022, then declined by 10.76% to $1.1 billion in 2023, then declined by 0.36% to $1.1 billion in 2024, then dropped by 1.52% to $1.1 billion in 2025, then slipped by 5.59% to $1.0 billion in 2026.
• Business Quant data shows FLGT's Common Equity at $1.0 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.1 billion in Q3 2025.